GC Biopharma Corp. /
Catalyst Biosciences, Inc.
GC Biopharma Corp. buys Catalyst Biosciences rare bleeding disorder program
- Price
- $6m
- Stage
- Closed
What happened
GC Biopharma Corp. acquired Catalyst Biosciences, Inc.’s legacy rare bleeding disorder program, including MarzAA, DalcA and CB-2679d-GT.
The agreement provides for $6 million in cash, including a closing payment and a hold-back subject to post-closing indemnification obligations.
The source
Everything on this page comes from the source below.
GC Biopharma Corp. buys Catalyst Biosciences rare bleeding disorder program
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly